Intercept Pharmaceuticals

FDA issues new warning on liver disease drugFDA is adding a Boxed Warning, its most prominent warning, on a liver disease medicine.
FDA committee recommends approving rare liver disease drugFDA advisory committee recently voted to recommend approval of obeticholic acid (Ocaliva, Intercept Pharmaceuticals, Inc.) for the treatment of primary biliary cholangitis (PBC). If approved, Ocaliva would be the first new treatment for PBC in nearly 20 years.